Phaseline

Companies › Absci

Absci: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABS-201
IgG1 monoclonal antibody targeting prolactin receptor (PRLR)
PRLRPhase 1Androgenetic Alopecia (AGA)Jul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07317544ABS-201Phase 1Androgenetic Alopecia (AGA)ImmunologyJul 2028

From the company's SEC filings

Cash and short-term investments of $201m on 2026-06-30; operating cash outflow about $109m a year; runway about 22 months at that burn, to May 2028

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

PRLR (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.